Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer.

ABSTRACT: Lung cancer remains the leading cause of cancer-related death in men and women, despite its constantly declining rates in incidence and mortality in the developed world. The past decade has witnessed an unprecedented rise in the development of molecular targeted therapies in various types of tumors. In non-small cell lung cancer (NSCLC), the greatest paradigm shift is the implementation of EGFR and ALK tyrosine kinase inhibitors in the first line and subsequent lines of therapy, with impressive results. Though less frequent than the molecular alterations in the aforementioned genes, a number of aberrations in potential oncogenic drivers has been discovered, namely mutations in the genes KRAS, BRAF, HER2, PI3KCA and DDR2, ROS1 and R

SUBMITTER: Gkolfinopoulos S 

PROVIDER: S-EPMC5952024 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature